A new drug designed to “seek and destroy” common cancers is being tested by TGen Clinical Research Services.

Un nouveau médicament fait pour chercher et détruire des cancers communs est présentement testé par Tgen clinical research services.

That includes breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers. The goal of the Phase 1 clinical trial is to determine if EP-100 is safe and effective for use among patients with solid cancer tumors and produces fewer side effects than chemotherapy or radiation treatments.

Cela inclus le cancer du de la de l'endomètre, de de la et des testicules. Le but de la phase 1 est de déterminer si le EP-100 est sécure et efficace pour l'utilisation sur des patients avec des tumeurs solides et produit moins d'effets secondaires que la chimio ou les radiations.

TCRS is a partnership of the Translational Genomics Research Institute and Scottsdale Healthcare. The partnership allows discoveries made by TGen and others around the world to reach patients through clinical trials in at Virginia G. Piper Cancer Center at Scottsdale Healthcare.

Dr. Ramesh K. Ramanathan, principal investigator for the trial in Scottsdale, said the drug is a membrane-disrupting peptide designed to “seek and destroy” cancer cells by targeting those with excessive luteinizing hormone releasing receptors, which are found in a wide range of cancers.

Up to 36 adult patients will be included in the study. EP-100 is produced by Esperance Pharmaceuticals of Baton Rouge, La. For more on the trial: www.clinicaltrials.gov. Patients seeking additional information about eligibility may contact patient care coordinator Joyce Ingold at 480-323-1339, 877-273-3713 or at jingold@shc.org.